Loading
Neuland Laboratories Limited Stock: price and insider trades · India
No insider purchase over the last 90 days. The latest, by Ms. Kamala Tayaramma Kommula, was filed 17 Dec 2025.
Insider Decl.
23
Thresholds
n/a
Buy Volume
€33,317
3 ops. · all time
Sell Volume
€29,295
2 ops. · all time
Who traded when
BuySaleMalabar India Fund Ltd1 sale
Kamala Tayaramma Kommula1 buy
Since the insiders bought
- +160.2%Entry ₹1,487.80 · Close at T+365 ₹3,870.60
- +200.1%Entry ₹1,270.25 · Close at T+365 ₹3,812.15
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Neuland Laboratories Limited Strong Buy (bullish), based on 4 analysts. Average price target: ₹24,678.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 12,211 of 26,280 companies
53.3
score / 100
Value28
Quality79
FCF yld-0.2%
Earn yld1.5%
EV/EBITDA40.9x
ROE·
Gross mgn51%
Net mgn19%
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
₹19,220.00
Analyst consensus
4 analystsStrong buy
₹24,100.00Target ₹24,678.50(+28%)₹25,819.00
Income statement
Revenue₹19.3B
Gross profit₹9.9B51% margin
EBITDA₹6B31% margin
Net income₹3.6B21.0% margin
Valuation
PER (trailing)49.5x
PER (forward)39.6x
P/Book13.2x
Beta0.28
Balance sheet & cash
Market cap₹246.6B
Total debt₹3B
Free Cash Flow-₹504.5M
Debt / Equity16%
Profitability & ownership
% insiders37.7%
% institutions28.0%
Last declaration on 28 September 2026
Declarations23 total
10,000 shares0EquityGiftSEBI:148872f0e2336ab94831eb250b4ef3b618b39d6a
10,000 shares0EquityGiftSEBI:8a427b8a33aedb9ef7d7f92a2eb76f076cd91ace
272,634 shares-MarketSEBI:71b210a8c7bae1c6a33d05a8c3a25831a173a796
96,000 shares@ ₹12,096.000.40% mcap100.0% of flowEquity SharesSEBI:0d03bc4158b3f6addbc30df99ba4686b38123175
12,500 sharesEquity SharesSEBI:01bdb601870693e555844b277f9eb5e28c5a21ff
12,500 sharesEquity SharesSEBI:1b4417e32bdcb6dacd4f115d563987d7c29b8ce3
6,000 sharesEquity SharesSEBI:3ffb0f8e4bf60b9568a71ea7e258f5222d70a0d0
6,000 sharesEquity SharesSEBI:ab258f291a136475f030fd22794377d20b9edb0c
Canonical exit: 16 Mar 2026 (T+90)
19,000 sharesEquity SharesSEBI:8ff392ad408e4de35f279005171a124bd29d08bb
10,000 sharesEquity SharesSEBI:d16fcd2495dd88f349f9a36ae772473f9aad4e7f
9,000 sharesEquity SharesSEBI:0c8a0447b4b3c0912a14f404d3d6df777f020dc5
79,462 sharesEquity SharesSEBI:a8183c7ee6b2f957ac05996d69d96ec9cfd3c0b7
79,462 sharesEquity SharesSEBI:934ede0188d194733db53239af64299555cf565b
79,573 sharesEquity SharesSEBI:937f1ade5fd27d8fd4141dd468331b4dcdfa8ba8
608,338 sharesEquity SharesSEBI:f0ed74686edecd2b16e432f0317ce49c95138929
2,565,979 sharesEquity SharesSEBI:b1b18cca7ccb4976049abd54f2accca88d35e644
3,253,890 sharesEquity SharesSEBI:d4ee2e51383c31eb24ed6b9884e015a66aa9f7ec
500 shares@ ₹5,375.31269.5% of flowEquity SharesSEBI:b62e4f859a13673fd4787828021ac0c5086cce7c
33,500 sharesEquity SharesSEBI:57408d1e1fb2cd09df11b0255c925a66e3578a67
33,500 sharesEquity SharesSEBI:4740fc962d7827bfb5c5860001716c52fa396f7d
1,267 shares@ ₹1,278.1176100.0% of flowEquity SharesSEBI:ab190c75a94d9b961156ab9da0d30bb8e745cbb3
Canonical exit: 27 Dec 2022 (T+90)
900 shares@ ₹1,154.543330.5% of flowEquity SharesSEBI:11b365ddbec7d14c614a7c28d07a379bc376bc6f
Canonical exit: 15 Nov 2022 (T+90)
77,634 sharesEquity SharesSEBI:e15bf82499cd43ade110b45e36267cb75534cfce
23 of 23 declarations
About Neuland Laboratories Limited
Neuland Laboratories Limited, an Indian healthcare company listed in Bombay with a market capitalisation of INR 246.6 billion, has a short record: 23 filings from 17 filers between March 22, 2022 and September 28, 2026, 18 of them of another kind. Insiders hold 37.7% of the capital.
Open-market trades can be counted: 3 purchases, 2 of them with an amount, worth EUR 33,317 in total, and 2 sales, only one with an amount, EUR 29,295, by Nirupama Sundar on December 4, 2023. The largest purchase is Payal Gupta's, EUR 20,464, on September 28, 2022; Nirupama Sundar bought EUR 12,852 on August 17, 2022. Purchases make 60% of open-market trades.
Read moreShow less
The most frequent filers are Promoters: Davuluri Saharsh Rao (3 filings), Gannabathula Venkata Krishna Rama Rao (2), Davuluri Ownership Trust (2) and Davuluri Ramamohan Rao (2), with no purchase or sale. The yearly pace is 3 filings in 2022, 3 in 2023, 11 in 2025 and 6 in 2026. The last twelve months hold 8, with 1 purchase and 1 sale. The median publication delay is 1 day.
